Welcome to the INA-RESPOND public website.
Current and expanding infectious disease profile in Indonesia warrants a sense of urgency and mandates that research be a priority to guide the management and prevention of disease to reduce morbidity and mortality. The purpose of Indonesia Research Partnership on Infectious Diseases (INA-RESPOND) is to bring together clinical and academic medical institutions to develop a robust collaborative infectious disease research network.
Research activity begins with the development of a clinical protocol that provides a plan for the essential aspects of the proposed research. A good research protocol should define a clear question and approach to answer it and also contain enough information to provide a clear and complete, but not overly detailed, description of the study. However,
Workshop Overview Currently growing knowledge and technology in the field of health is supported by various number of health research, both interventional and observational, involving one or many research centers (multi-center). Some researchers have also started examining human genetics or genomes or carrying out further research of stored biologic materials. Sensitive ethical issues may arise
The INA-RESPOND network is inviting all interested Indonesian government and private hospitals to participate in our HIV study entitled, “A Prospective Observational Cohort Study On HIV Infection And Risk Related Coinfections/Comorbidities In Indonesia” (INA-PROACTIVE). Send an email to ina104sitesupport@ina-respond.net or call our head office at +62 21 4287 9189 (Mr. Caleb/Ikhsan or Ms. Lois) for
On July 21-22, 2017, INA-RESPOND Secretariat invited four active TRIPOD sites to attend the first TRIPOD interim analysis meeting. The four active sites are RSUP Sanglah Denpasar, Bali (site 520); RSUP dr. Kariadi, Semarang (site 560); RSUD Soetomo, Surabaya (site 570); and RSUP dr. Sardjito, Yogyakarta (site 580). The Principal Investigator (PI) or Co-PI and
To identify the etiology of acute febrile illness cases and evaluate clinical manifestations and outcomes.
To determine the causes of community-acquired sepsis and severe sepsis in adults and pediatrics across Southeast Asia.
To estimate the proportion of MDR TB amongst treatment naïve new treatment naïve and previously treated cases.
